The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
On May 26, 2022, the European Commission (EC) granted a conditional marketing authorization to ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed/refractory multiple myeloma (MM).1 This decision is made 2 months after the favorable opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
Cilta-cel’s approval is based on the results of the CARTITUDE-1 trial and depends on the provision of comprehensive and long-term data at a later stage. The current indication is for treating adult patients with relapsed/refractory MM who have received ≥3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.1
Updated data from both the CARTITUDE-1 and CARTITUDE-2 trials are expected to be presented at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA)2022 Hybrid Congress.2,3
Review here the ongoing and planned clinical trials investigating cilta-cel for the treatment of patients with MM.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content